Nephroprotective measures in patients with type 2 diabetes were reviewed by Prof. Ariane SULTAN during the annual meeting of the Société Francophone du Diabète (SFD), held in Paris from April 1 to 4, 2025.
The assessment of kidney function remains insufficiently performed in patients with type 2 diabetes, according to Study ENTRED 3.
SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors — also known as gliflozins) are now considered first-line agents for kidney protection. They help prevent the risk of acute and/or chronic kidney failure and slow its progression toward end-stage renal disease, thanks to their proven efficacy supported by numerous expert reviews and clinical guidelines.
Prof. Bruno VERGÈS, President of the FFRD, discussed fluid and electrolyte disorders in patients with type 2 diabetes (T2D) who suffer from impaired kidney function:
- Hyponatremia: a decrease in blood sodium levels (natremia) below 135mmol/L,
- Hypomagnesemia: an abnormally low blood magnesium level (plasma concentration) below
0.65mmol/L, - Hyperkalemia: an elevated potassium level in the blood.
Prof. Olivier BOURRON, recipient of an FFRD grant in 2023, reminded that T2D patients with peripheral arterial disease and neuropathy remain at high cardiovascular and renal risk, and at very high risk of foot complications.
Early intervention is essential. SGLT2 inhibitors play a key role in therapeutic strategies, provided that careful podiatric monitoring is maintained.
Video from Len axis in Diabétologie Pratique.